Viking Therapeutics (VKTX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
11 Nov, 2026Pipeline and market
VK2735 is a dual GLP-1/GIP agonist for obesity, in Phase 3 testing as both a subcutaneous injection and an oral tablet; VK3019 is an amylin agonist in Phase 1.
VANQUISH subcutaneous Phase 3 trials are fully enrolled; SUNRISE oral Phase 3 trials began in 4Q26, with topline data expected in 2028.
Obesity affects 1B+ adults globally and is associated with 200+ comorbidities; current therapy penetration is below 5%, and most patients discontinue within one year.
Obesity market projections show 16% CAGR and $150B+ in 2035E sales; VK2735 is positioned to pursue share with oral and injectable formulations.
VK2735 subcutaneous results
In the 13-week VENTURE Phase 2 trial, weight loss reached 14.7% from baseline and 13.1% placebo-adjusted at the 15 mg dose; all dose groups were significant vs. placebo.
Weight loss was progressive across all cohorts, with no plateau through Week 13; statistical significance vs. placebo began in Week 1 and continued through Week 13.
In the VK2735-102 maintenance study, Week 21 weight loss reached 17.8% at 17.5 mg and 18.7% at 20 mg; continued 17.5 mg weekly dosing produced 21.7% loss at Week 33.
After transition from weekly dosing, up to 96.7% of Week 21 weight loss was maintained with every-other-week dosing and up to 90.2% with monthly dosing through Week 33.
VANQUISH-1 enrolled 4,500+ participants and VANQUISH-2 approximately 1,000; both completed enrollment, with data expected in 2H27.
VK2735 oral results
In the 13-week oral Phase 2 study, mean weight loss reached 12.2%; loss was progressive without a plateau, and doses above 15 mg were statistically significant vs. placebo at all time points.
Most weight loss was maintained for three weeks after dosing ended; an exploratory 90 mg-to-30 mg daily maintenance cohort continued gradual weight loss through Week 13.
The oral study reported 99% of GI adverse events as mild or moderate; doses up to 60 mg had GI tolerability similar to placebo, and rates generally declined over time.
SUNRISE-1 and SUNRISE-2 began in 4Q26, each targeting 560 participants over 68 weeks; data are expected in 2028.
A subcutaneous-to-oral maintenance study is underway, with data expected in 2027.
Latest events from Viking Therapeutics
- VK2735 maintenance supports less-frequent dosing ahead of 2027–28 Phase 3 readouts.VKTX
Jefferies Global Healthcare Conference - VK2735 Phase 3 advances; $960M liquidity cushions investment and license risk.VKTX
Q3 2026 - VK2735 showed durable weight loss with less-frequent dosing as obesity Phase 3 trials advance.VKTX
Corporate presentation - Up to 22% weight loss and 97% maintenance achieved with flexible, well-tolerated VK2735 dosing.VKTX
Study result - Obesity program VK2735 advances in phase III with broad market and manufacturing strategies.VKTX
Morgan Stanley 24th Annual Global Healthcare Conference - VK2735 delivers up to 14.7% mean weight loss in Phase 2, with Phase 3 trials fully enrolled.VKTX
Corporate presentation - Phase III obesity trials fully enrolled; net loss rose as R&D spending surged, with $502M in cash.VKTX
Q2 2026 - VK2735 delivers up to 15% weight loss in late-stage trials with strong safety and cash reserves.VKTX
Corporate presentation - Q3 net loss rose to $90.8M as R&D spending surged; cash reserves remain strong at $715M.VKTX
Q3 2025